Leightonx
liked
$T14.SG$
(a) Revenue:
The Group’s revenue in the third quarter of FY2021 (“3Q FY2021”) was approximately RMB 1,712 million, an increase of approximately RMB 45 million, or 3%, from RMB 1,667 million in the third quarter of FY2020 (“3Q FY2020”). For the 9 months ended 30 September 2021 (“9M 2021”), the Group recorded a revenue of approximately RMB 5,352 million, an increase of approximately RMB 395 million, approximately 8% over the corresponding period in FY2020. The increase in revenue as compared to the corresponding period last year was primarily because the revenue in the corresponding period last year was affected by the COVID-19 pandemic.
(b) Gross Profit Margin:
The Group’s gross profit in 3Q FY2021 increased by approximately 19% from approximately RMB 585 million in 3Q FY2020 to approximately RMB 696 million. For 9M 2021, the Group’s gross profit was approximately RMB 2,202 million compared to approximately RMB 1,935 million in the corresponding period of FY2020, with an increase of approximately 14% amounting to approximately RMB 268 million. The gross profit margin has increased from 39% in the 9 months ended 30 September 2020 (“9M 2020”) to 41% in 9M 2021.
(a) Revenue:
The Group’s revenue in the third quarter of FY2021 (“3Q FY2021”) was approximately RMB 1,712 million, an increase of approximately RMB 45 million, or 3%, from RMB 1,667 million in the third quarter of FY2020 (“3Q FY2020”). For the 9 months ended 30 September 2021 (“9M 2021”), the Group recorded a revenue of approximately RMB 5,352 million, an increase of approximately RMB 395 million, approximately 8% over the corresponding period in FY2020. The increase in revenue as compared to the corresponding period last year was primarily because the revenue in the corresponding period last year was affected by the COVID-19 pandemic.
(b) Gross Profit Margin:
The Group’s gross profit in 3Q FY2021 increased by approximately 19% from approximately RMB 585 million in 3Q FY2020 to approximately RMB 696 million. For 9M 2021, the Group’s gross profit was approximately RMB 2,202 million compared to approximately RMB 1,935 million in the corresponding period of FY2020, with an increase of approximately 14% amounting to approximately RMB 268 million. The gross profit margin has increased from 39% in the 9 months ended 30 September 2020 (“9M 2020”) to 41% in 9M 2021.
3
Leightonx
liked
11
1
Leightonx
liked
Established COVID-19 vaccine makers have come under pressure after $PFE.US$ and a United Nations-backed public health organization announced a licensing pact to allow generic-drugmakers to produce cheaper versions of the company’s experimental COVID-19 pill.
$MRNA.US$ , $AZN.US$ , and Pfizer’s partner in COVID-19 vaccine development $BNTX.US$ have lost ~1.4%, ~3.1%, and ~1.0% in the pre-market, respectively. $JNJ.US$ is trading flat.
The licensing deal by Pfizer to enable wider access to its COVID-19 therapeutic follows a similar deal from the rival drugmaker $MRK.US$ for its investigational pill, molnupiravir. Merck has shed ~1.0% in early trading.
The shares of early-stage developers of oral COVID-19 therapies such as $AVIR.US$ / $RHHBY.US$ , $RDHL.US$ , and $Adagio Therapeutics.US$ are also expected to open lower.
Stocks to watch: Established manufacturers of COVID-19 antibody treatments such as $VIR.US$ , $REGN.US$ , $LLY.US$ as well as $GILD.US$ , which produces the intravenously administered COVID-19 therapy Remdesivir.
In terms of effectiveness, $PFE.US$ and its rival $MRK.US$ have demonstrated about 89% and ~50% effectiveness for their oral COVID-19 drugs, PAXLOVID, and molnupiravir in late-stage trials, respectively.
$MRNA.US$ , $AZN.US$ , and Pfizer’s partner in COVID-19 vaccine development $BNTX.US$ have lost ~1.4%, ~3.1%, and ~1.0% in the pre-market, respectively. $JNJ.US$ is trading flat.
The licensing deal by Pfizer to enable wider access to its COVID-19 therapeutic follows a similar deal from the rival drugmaker $MRK.US$ for its investigational pill, molnupiravir. Merck has shed ~1.0% in early trading.
The shares of early-stage developers of oral COVID-19 therapies such as $AVIR.US$ / $RHHBY.US$ , $RDHL.US$ , and $Adagio Therapeutics.US$ are also expected to open lower.
Stocks to watch: Established manufacturers of COVID-19 antibody treatments such as $VIR.US$ , $REGN.US$ , $LLY.US$ as well as $GILD.US$ , which produces the intravenously administered COVID-19 therapy Remdesivir.
In terms of effectiveness, $PFE.US$ and its rival $MRK.US$ have demonstrated about 89% and ~50% effectiveness for their oral COVID-19 drugs, PAXLOVID, and molnupiravir in late-stage trials, respectively.
63
8
Leightonx
liked
Hang Seng Index: Lowered the weights of Tencent Holdings (00700.HK), Alibaba (09988.HK), and Meituan (03690.HK) in the Hang Seng Index from 8.55%, 8.05%, and 9.5% respectively to 8%. The weights of JD (09618.HK) and NetEase (09999.HK) in the Hang Seng Index were 1.54% and 0.64%, respectively.
$TENCENT.HK$
$BABA.US$
$BABA-SW.HK$
$MEITUAN-W.HK$
$MPNGF.US$
$JD.US$
$JD-SW.HK$
$NTES-S.HK$
$NTES.US$
$TENCENT.HK$
$BABA.US$
$BABA-SW.HK$
$MEITUAN-W.HK$
$MPNGF.US$
$JD.US$
$JD-SW.HK$
$NTES-S.HK$
$NTES.US$
Translated
79
1
Leightonx
liked
$PFE.US$ $GILD.US$ $MRK.US$ $VIR.US$
Calculating the statistical error, it is similar or stronger than remdesivir alone. (It is not ruled out that Gilead will use HIV medicine to make a better one in the future)
The MSD case was scrapped. So sorry for MSD shareholders. They have had to be sued for a long time. Fortunately, value stocks can always pay for themselves in a year or two. MSD's AIDS program also deserves attention.
I lost all of my earnings from Pfizer to Grandpa VIR. I picked up VIR's flying knife, go ahead, go ahead
update. Pfizer is a combination of PF-07321332 and the HIV drug ritonavir (unpatented). Note that last year's World Health Organization solidary solidarity trial concluded that lopinavir + ritonavir was not effective; it was a proper academic misconduct. Biden is strong; sure enough, he knew something in advance. I just think everyone really has to check their holdings. Stocks that have benefited from the pandemic have to take profits in a timely manner; if you don't want to step on PTON, you can't run at all.
According to the experimental data, in fact, the PFE, MRK, and WHO solidarity all played a trick, comparing chickens to ducks. Can data from Americans, Indians, and South Americans be pooled together?
In terms of valuation. A signed contract will definitely be executed as long as it is approved. If the government has a budget, who cares which one is strong? Currently, there is still a shortage of medicines, and there is a shortage of antibodies. That's why REGN VIR was fried for a short time. How much is this Pfizer worth? As a covid drug, the market is definitely overvalued. It goes up a wave and then falls. Then Pfizer will do more experiments, eat more of this fish, and make a fortune by making a broad spectrum anti-virus. So is MSD. MRNA and BNTX are good companies, but they always have to be valued, and why don't they increase sales at high prices? Gilead's side... if it didn't fall, it was a huge victory. The picture was ruined again by MSD's news... but anyway, it's cheap, hold it
Calculating the statistical error, it is similar or stronger than remdesivir alone. (It is not ruled out that Gilead will use HIV medicine to make a better one in the future)
The MSD case was scrapped. So sorry for MSD shareholders. They have had to be sued for a long time. Fortunately, value stocks can always pay for themselves in a year or two. MSD's AIDS program also deserves attention.
I lost all of my earnings from Pfizer to Grandpa VIR. I picked up VIR's flying knife, go ahead, go ahead
update. Pfizer is a combination of PF-07321332 and the HIV drug ritonavir (unpatented). Note that last year's World Health Organization solidary solidarity trial concluded that lopinavir + ritonavir was not effective; it was a proper academic misconduct. Biden is strong; sure enough, he knew something in advance. I just think everyone really has to check their holdings. Stocks that have benefited from the pandemic have to take profits in a timely manner; if you don't want to step on PTON, you can't run at all.
According to the experimental data, in fact, the PFE, MRK, and WHO solidarity all played a trick, comparing chickens to ducks. Can data from Americans, Indians, and South Americans be pooled together?
In terms of valuation. A signed contract will definitely be executed as long as it is approved. If the government has a budget, who cares which one is strong? Currently, there is still a shortage of medicines, and there is a shortage of antibodies. That's why REGN VIR was fried for a short time. How much is this Pfizer worth? As a covid drug, the market is definitely overvalued. It goes up a wave and then falls. Then Pfizer will do more experiments, eat more of this fish, and make a fortune by making a broad spectrum anti-virus. So is MSD. MRNA and BNTX are good companies, but they always have to be valued, and why don't they increase sales at high prices? Gilead's side... if it didn't fall, it was a huge victory. The picture was ruined again by MSD's news... but anyway, it's cheap, hold it
Translated
18
Leightonx
liked
The profits Big Pharma is making from COVID-19 vaccines will be revealed this week as both $PFE.US$and $MRNA.US$report Q3 earnings. Analysts are expecting the two companies (Pfizer today, Moderna tomorrow) to disclose a collective $18B in vaccine sales, a figure which is comparable to their last two quarters - combined. Last week, $JNJ.US$said it saw more than $500M in Q3 vaccine sales, nearly double the $264M it made in the first half. All eyes on Pfizer's COVID-19 vaccine business ahead of Q3 results.
Bigger picture:COVID-19 vaccine revenues are more important financially to Moderna, since the jab is its only commercially approved product. Shares also slid yesterday after the company chose to delay the filing of its Emergency Use Authorization request for use in the 6 – 11-year age group. It made the decision upon hearing that the FDA would already need additional time to evaluate the data in adolescents aged 12 to 17, meaning a review for that age category is unlikely to be complete before Jan. 2022. (Pfizer's vaccine was FDA-approved for kids last week).
Investors were also be on the lookout for comments on the vaccine sales for Q4 and 2022, as well as production expectations for younger patients and coverage for more of the globe. Other COVID drugs are also bringing in billions, like $GILD.US$Veklury antiviral treatment, which is administered to hospitalized patients (had sales of $1.9B in Q3). $MRK.US$also predicts its COVID-19 pill, called molnupiravir, could bring in up to $7B in sales next year if granted regulatory authorization.
Rosy sales outlook?"Starting the week of Nov. 8, the kids vaccination program will be fully up and running," White House coronavirus response coordinator Jeff Zients said in a statement. The CDC will meet today to assess approval for Pfizer-BioNTech's ( $PFE.US$ $BNTX.US$) vaccine for 5- to 11-year-olds and the Biden administration has already begun transferring 15M doses to facilitate immunizations at pediatricians' offices, pharmacies, hospitals and health centers. Unlike a pledge from Johnson & Johnson, both Pfizer and Moderna have chosen to profit from COVID-19 vaccine sales.
Bigger picture:COVID-19 vaccine revenues are more important financially to Moderna, since the jab is its only commercially approved product. Shares also slid yesterday after the company chose to delay the filing of its Emergency Use Authorization request for use in the 6 – 11-year age group. It made the decision upon hearing that the FDA would already need additional time to evaluate the data in adolescents aged 12 to 17, meaning a review for that age category is unlikely to be complete before Jan. 2022. (Pfizer's vaccine was FDA-approved for kids last week).
Investors were also be on the lookout for comments on the vaccine sales for Q4 and 2022, as well as production expectations for younger patients and coverage for more of the globe. Other COVID drugs are also bringing in billions, like $GILD.US$Veklury antiviral treatment, which is administered to hospitalized patients (had sales of $1.9B in Q3). $MRK.US$also predicts its COVID-19 pill, called molnupiravir, could bring in up to $7B in sales next year if granted regulatory authorization.
Rosy sales outlook?"Starting the week of Nov. 8, the kids vaccination program will be fully up and running," White House coronavirus response coordinator Jeff Zients said in a statement. The CDC will meet today to assess approval for Pfizer-BioNTech's ( $PFE.US$ $BNTX.US$) vaccine for 5- to 11-year-olds and the Biden administration has already begun transferring 15M doses to facilitate immunizations at pediatricians' offices, pharmacies, hospitals and health centers. Unlike a pledge from Johnson & Johnson, both Pfizer and Moderna have chosen to profit from COVID-19 vaccine sales.
23
2
Leightonx
liked
$BNTX.US$ was the best performing large pharma/biotech company in October, with a return of ~11.5%.
The German company continues to benefit from sales of its COVID-19 vaccine. October marked the first full month booster shots were available in the U.S., and indications are the uptake is significant.
On Oct. 29, the FDA also granted authorization to BioNTech and its partner $PFE.US$ for vaccinations in children between the ages of 5 and 11.
Pfizer eked out a small gain of 0.6% in the month.
The next best performer in October was $GSK.US$ with a ~10.5% return.
In mid October, a report surfaced that there was keen interest in its consumer health business. Later in the month, GSK raised its 2021 earnings guidance.
Just behind GSK was $LLY.US$ with a ~10.4% gain.
A highlight for Lilly in the month was its announcement it began a rolling submission of its Alzheimer's candidate donanemab.
Rounding out the top 5 are $REGN.US$ and $MRK.US$ with returns of, respectively, 9.5% and 6.3%.
The worst performing large pharma biotech stock of October was $BMY.US$ with a 4% loss.
Late in the month, Bristol hit a 52-week low even though it beat Q3 2021 earnings estimates. Shares are down ~7.9% year to date.
$AMGN.US$ came in second place losing 3.2%.
Shares hit a 52-week low on Oct. 12 and almost fell below $200 per share.
The third worst performer was $GILD.US$ which lost 1.8%.
While Gilead boosted its FY 2021 financial outlook, Cantor Fitzgerald lowered its price target due to a likely delay in the launch of a cancer drug.
Rounding out the top five worst performers were Pfizer and $NVS.US$ with gains of, respectively, 0.6% and 1.6%.
The German company continues to benefit from sales of its COVID-19 vaccine. October marked the first full month booster shots were available in the U.S., and indications are the uptake is significant.
On Oct. 29, the FDA also granted authorization to BioNTech and its partner $PFE.US$ for vaccinations in children between the ages of 5 and 11.
Pfizer eked out a small gain of 0.6% in the month.
The next best performer in October was $GSK.US$ with a ~10.5% return.
In mid October, a report surfaced that there was keen interest in its consumer health business. Later in the month, GSK raised its 2021 earnings guidance.
Just behind GSK was $LLY.US$ with a ~10.4% gain.
A highlight for Lilly in the month was its announcement it began a rolling submission of its Alzheimer's candidate donanemab.
Rounding out the top 5 are $REGN.US$ and $MRK.US$ with returns of, respectively, 9.5% and 6.3%.
The worst performing large pharma biotech stock of October was $BMY.US$ with a 4% loss.
Late in the month, Bristol hit a 52-week low even though it beat Q3 2021 earnings estimates. Shares are down ~7.9% year to date.
$AMGN.US$ came in second place losing 3.2%.
Shares hit a 52-week low on Oct. 12 and almost fell below $200 per share.
The third worst performer was $GILD.US$ which lost 1.8%.
While Gilead boosted its FY 2021 financial outlook, Cantor Fitzgerald lowered its price target due to a likely delay in the launch of a cancer drug.
Rounding out the top five worst performers were Pfizer and $NVS.US$ with gains of, respectively, 0.6% and 1.6%.
24
5
Leightonx
liked
Weekly market recap
Stock futures edged lower in overnight trading Sunday after the Dow Jones Industrial Average notched its third positive week in a row at a record high.
Wall Street is coming off a winning week on the back of strong corporate earnings. The blue-chip $DOW.US$ gained more than 1% last week and closed Friday at a record. The $.SPX.US$ rallied 1.7% last week, also posting its third straight positive week and hitting an all-time high Friday.
Of the 117 companies in the S&P 500 that have reported earnings to date, 84% posted numbers that beat expectations, according to Refinitiv. S&P 500 companies are expected to grow profit by about 35% in the third quarter.
Here's a look at the return of S&P 500 sectors
This week ahead in focus
Some of the biggest technology companies are slated to report earnings this week, including $Meta Platforms.US$, $GOOG.US$, $MSFT.US$, $AMZN.US$ and $AAPL.US$. A third of the Dow companies also is set to release quarterly results this week, including $CAT.US$, $KO.US$, $BA.US$ and $MCD.US$.
Economists and Fed watchers will also be paying attention on Wednesday, when the minutes from the Federal Open Market Committee September meeting will be released. Finally, the annual meetings of the World Bank Group and the International Monetary Fund will run virtually all week.
Economic data out this week includes the Conference Board's Consumer Confidence Index for October on Tuesday, the Census Bureau's durable-goods report for September on Wednesday, and the Bureau of Economic Analysis' preliminary estimate for third-quarter GDP on Thursday.
Economists' consensus estimate is for a seasonally adjusted annual growth rate of 4%, after the economy grew 6.7% in the second quarter.
Monday 10/25
Mega-cap tech companies headline the week's quarterly results starting with Facebook, which reports after the close. Alphabet and Microsoft follow on Tuesday, and Amazon.com and Apple on Thursday.
$CDNS.US$, $KMB.US$, and $OTIS.US$release quarterly results.
Tuesday 10/26
$MMM.US$, $AMD.US$, $AMP.US$, $COF.US$, $CB.US$, $ECL.US$, $LLY.US$, $GE.US$, $HAS.US$, $IVZ.US$, $LMT.US$, $MSCI.US$, $NOVN.US$, $RTX.US$, $SPGI.US$, $SHW.US$, $TXN.US$, $TWTR.US$, $UPS.US$, and $V.US$ report earnings.
The Census Bureau reports sales of new single-family houses for September. Consensus estimate is for a seasonally adjusted annual rate of 775,000 homes sold, 35,000 more than the August figure.
The Conference Board releases its Consumer Confidence Index for October. Expectations are for a 110 reading, similar to the September data. The index is 15% lower than its recent peak in June, with concern about the spread of the Delta variant and inflation dampening consumer optimism.
S&P CoreLogic releases its Case-Shiller National Home Price Index for August. Economists forecast a 20% year-over-year rise, a tick higher than July's 19.7% increase. If that estimate proves correct, it would be the fifth consecutive monthly record gain for the index.
Wednesday 10/27
$ADP.US$, Boeing, $BMY.US$, $CME.US$, Coca-Cola, $EBAY.US$, $F.US$, $GD.US$, $GM.US$, $HLT.US$, $IP.US$, $KHC.US$, McDonald's, $NSC.US$, $ODFL.US$, $NOW.US$, $SPOT.US$, and $TMO.US$ release quarterly results.
The Census Bureau releases the durable-goods report for September. New orders for manufactured durable goods are expected to decline 0.5% month over month to $262 billion, after a 1.8% gain in August. Excluding transportation, new orders are seen rising 0.8%, above August's 0.3% gain.
Thursday 10/28
$MO.US$, $AMT.US$, Caterpillar, $CMCSA.US$, $GILD.US$, $ICE.US$, $MA.US$, $MRK.US$, $MCO.US$, $NEM.US$, $NOC.US$, $SNY.US$, $SHOP.US$, $SBUX.US$, and $YUM.US$ hold conference calls to discuss earnings.
The Bureau of Economic Analysis reports its preliminary estimate for third-quarter GDP. Consensus estimate is for a seasonally adjusted annual growth rate of 4%, after the economy grew 6.7% in the second quarter.
Friday 10/29
$ABBV.US$, $CBOE.US$, $CHTR.US$, $CVX.US$, $CL.US$, $XOM.US$, $LHX.US$, and $WY.US$ report quarterly results.
Source: CNBC, Barron's
Stock futures edged lower in overnight trading Sunday after the Dow Jones Industrial Average notched its third positive week in a row at a record high.
Wall Street is coming off a winning week on the back of strong corporate earnings. The blue-chip $DOW.US$ gained more than 1% last week and closed Friday at a record. The $.SPX.US$ rallied 1.7% last week, also posting its third straight positive week and hitting an all-time high Friday.
Of the 117 companies in the S&P 500 that have reported earnings to date, 84% posted numbers that beat expectations, according to Refinitiv. S&P 500 companies are expected to grow profit by about 35% in the third quarter.
Here's a look at the return of S&P 500 sectors
This week ahead in focus
Some of the biggest technology companies are slated to report earnings this week, including $Meta Platforms.US$, $GOOG.US$, $MSFT.US$, $AMZN.US$ and $AAPL.US$. A third of the Dow companies also is set to release quarterly results this week, including $CAT.US$, $KO.US$, $BA.US$ and $MCD.US$.
Economists and Fed watchers will also be paying attention on Wednesday, when the minutes from the Federal Open Market Committee September meeting will be released. Finally, the annual meetings of the World Bank Group and the International Monetary Fund will run virtually all week.
Economic data out this week includes the Conference Board's Consumer Confidence Index for October on Tuesday, the Census Bureau's durable-goods report for September on Wednesday, and the Bureau of Economic Analysis' preliminary estimate for third-quarter GDP on Thursday.
Economists' consensus estimate is for a seasonally adjusted annual growth rate of 4%, after the economy grew 6.7% in the second quarter.
Monday 10/25
Mega-cap tech companies headline the week's quarterly results starting with Facebook, which reports after the close. Alphabet and Microsoft follow on Tuesday, and Amazon.com and Apple on Thursday.
$CDNS.US$, $KMB.US$, and $OTIS.US$release quarterly results.
Tuesday 10/26
$MMM.US$, $AMD.US$, $AMP.US$, $COF.US$, $CB.US$, $ECL.US$, $LLY.US$, $GE.US$, $HAS.US$, $IVZ.US$, $LMT.US$, $MSCI.US$, $NOVN.US$, $RTX.US$, $SPGI.US$, $SHW.US$, $TXN.US$, $TWTR.US$, $UPS.US$, and $V.US$ report earnings.
The Census Bureau reports sales of new single-family houses for September. Consensus estimate is for a seasonally adjusted annual rate of 775,000 homes sold, 35,000 more than the August figure.
The Conference Board releases its Consumer Confidence Index for October. Expectations are for a 110 reading, similar to the September data. The index is 15% lower than its recent peak in June, with concern about the spread of the Delta variant and inflation dampening consumer optimism.
S&P CoreLogic releases its Case-Shiller National Home Price Index for August. Economists forecast a 20% year-over-year rise, a tick higher than July's 19.7% increase. If that estimate proves correct, it would be the fifth consecutive monthly record gain for the index.
Wednesday 10/27
$ADP.US$, Boeing, $BMY.US$, $CME.US$, Coca-Cola, $EBAY.US$, $F.US$, $GD.US$, $GM.US$, $HLT.US$, $IP.US$, $KHC.US$, McDonald's, $NSC.US$, $ODFL.US$, $NOW.US$, $SPOT.US$, and $TMO.US$ release quarterly results.
The Census Bureau releases the durable-goods report for September. New orders for manufactured durable goods are expected to decline 0.5% month over month to $262 billion, after a 1.8% gain in August. Excluding transportation, new orders are seen rising 0.8%, above August's 0.3% gain.
Thursday 10/28
$MO.US$, $AMT.US$, Caterpillar, $CMCSA.US$, $GILD.US$, $ICE.US$, $MA.US$, $MRK.US$, $MCO.US$, $NEM.US$, $NOC.US$, $SNY.US$, $SHOP.US$, $SBUX.US$, and $YUM.US$ hold conference calls to discuss earnings.
The Bureau of Economic Analysis reports its preliminary estimate for third-quarter GDP. Consensus estimate is for a seasonally adjusted annual growth rate of 4%, after the economy grew 6.7% in the second quarter.
Friday 10/29
$ABBV.US$, $CBOE.US$, $CHTR.US$, $CVX.US$, $CL.US$, $XOM.US$, $LHX.US$, and $WY.US$ report quarterly results.
Source: CNBC, Barron's
+2
238
8
Leightonx
liked
6
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)